Everest Organics
BSE: EVERESTO · Pharmaceuticals
Limited coverage
We are not actively covering this company or have limited coverage today. Click to request coverage.
Snapshot
Unlock Everest Organics's vital signs
Growth · Profitability · Valuation · Strength · Conviction
Company Overview
Business
Everest Organics Limited is a Hyderabad-based pharmaceutical company specialising in the manufacturing of active pharmaceutical ingredients (APIs) and bulk drug intermediates. The company maintains a strong focus on the anti-ulcerative segment while also producing anti-virals, anti-fungals, and anti-bacterial agents for global markets.
Business Model
The company generates revenue through the cost-effective chemical synthesis and sale of APIs and intermediates to both domestic and international pharmaceutical markets. It leverages its regulatory-compliant manufacturing facility in Telangana to support a diverse product portfolio and a growing generic drug pipeline.
Growth Outlook
Growth is driven by the expansion of research and development capabilities aimed at strengthening the company's generic drug pipeline. The company continues to focus on maintaining international regulatory compliance to support its export operations across Asia, Europe, and the Americas.
Key Risks
- Regulatory Compliance Risk. Failure to maintain international regulatory standards at manufacturing facilities could lead to export restrictions or loss of market access.
- Raw Material Price Volatility. Fluctuations in the cost of chemical precursors and raw materials can significantly impact profit margins in the API manufacturing sector.
- Competitive Pressure. The pharmaceutical industry faces intense competition from low-cost generic manufacturers, which may exert downward pressure on product pricing.
- Foreign Exchange Risk. As an exporter to multiple continents, the company is exposed to currency fluctuations that may affect the profitability of international sales.
Start your research today
Unlock AI insights, financials, peers and live data on Everest Organics and 5,000+ companies — free.
Key Metrics
REVENUE
₹196 Cr
TTM · standalone
NET PROFIT
₹6 Cr
TTM · standalone
EPS
₹6.32
TTM · standalone
RETURN ON EQUITY
7.8%
TTM · standalone
RETURN ON CAPITAL EMPLOYED
17.1%
TTM · standalone
P/E
51.1x
Q4 FY26 · standalone
EV/EBITDA
12.9x
Q4 FY26 · standalone
EBITDA MARGIN
10.7%
TTM · standalone
NET PROFIT MARGIN
5.4%
Q4 FY26 · standalone
DEBT TO EQUITY
0.7x
Q4 FY26 · standalone
Peers · Pharmaceuticals
| Company | Mkt Cap | P/E | EV/EBITDA | Rev Gr YoY | EBITDA Mgn | ROE | ROCE | 1Y Return |
|---|---|---|---|---|---|---|---|---|
Everest OrganicsEVERESTO | ₹272 Cr | 44.40 | 15.30 | 23.0% | 10.7% | 7.8% | 17.1% | -28.9% |
Albert DavidALBERTDAVD | ₹513 Cr | 22.73 | 13.48 | 11.4% | 11.0% | 5.8% | 7.5% | +12.1% |
Jenburkt Pharmaceuticals LimitedJENBURPH | ₹463 Cr | 13.31 | 8.46 | — | 32.0% | 17.6% | 23.2% | -4.3% |
Haleos Labs LimitedHALEOSLABS | ₹452 Cr | 28.60 | 12.72 | -3.1% | 13.6% | 7.4% | 10.3% | — |
TranschemTRANSCHEM | ₹424 Cr | 98.76 | 68.07 | -100.0% | 177.7% | 5.3% | 7.0% | +592.6% |
Medicamen BiotecMEDICAMEQ | ₹338 Cr | 33.59 | 15.53 | 24.7% | 11.3% | 4.1% | 6.2% | -27.9% |
As of Q4 FY26
Financials
Everest Organics
BSE: EVERESTO · Pharmaceuticals
Limited coverage
We are not actively covering this company or have limited coverage today. Click to request coverage.
Snapshot
Unlock Everest Organics's vital signs
Growth · Profitability · Valuation · Strength · Conviction
Company Overview
Business
Everest Organics Limited is a Hyderabad-based pharmaceutical company specialising in the manufacturing of active pharmaceutical ingredients (APIs) and bulk drug intermediates. The company maintains a strong focus on the anti-ulcerative segment while also producing anti-virals, anti-fungals, and anti-bacterial agents for global markets.
Business Model
The company generates revenue through the cost-effective chemical synthesis and sale of APIs and intermediates to both domestic and international pharmaceutical markets. It leverages its regulatory-compliant manufacturing facility in Telangana to support a diverse product portfolio and a growing generic drug pipeline.
Growth Outlook
Growth is driven by the expansion of research and development capabilities aimed at strengthening the company's generic drug pipeline. The company continues to focus on maintaining international regulatory compliance to support its export operations across Asia, Europe, and the Americas.
Key Risks
- Regulatory Compliance Risk. Failure to maintain international regulatory standards at manufacturing facilities could lead to export restrictions or loss of market access.
- Raw Material Price Volatility. Fluctuations in the cost of chemical precursors and raw materials can significantly impact profit margins in the API manufacturing sector.
- Competitive Pressure. The pharmaceutical industry faces intense competition from low-cost generic manufacturers, which may exert downward pressure on product pricing.
- Foreign Exchange Risk. As an exporter to multiple continents, the company is exposed to currency fluctuations that may affect the profitability of international sales.
Start your research today
Unlock AI insights, financials, peers and live data on Everest Organics and 5,000+ companies — free.
Key Metrics
REVENUE
₹196 Cr
TTM · standalone
NET PROFIT
₹6 Cr
TTM · standalone
EPS
₹6.32
TTM · standalone
RETURN ON EQUITY
7.8%
TTM · standalone
RETURN ON CAPITAL EMPLOYED
17.1%
TTM · standalone
P/E
51.1x
Q4 FY26 · standalone
EV/EBITDA
12.9x
Q4 FY26 · standalone
EBITDA MARGIN
10.7%
TTM · standalone
NET PROFIT MARGIN
5.4%
Q4 FY26 · standalone
DEBT TO EQUITY
0.7x
Q4 FY26 · standalone
Peers · Pharmaceuticals
As of Q4 FY26